Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 8/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 3/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 6/20 | 0.33 |
| ▸ | RAB9A | P51151 | 6/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22981209 | 0.84 | ESR1 (0.53) | ABHD6ESR1ESR2 | |
| SCHEMBL28534853 | 0.82 | ABHD6 (0.35) | ABHD6AKR1C3ESR1ESR2NOTUM | |
| SCHEMBL19949068 | 0.82 | ABHD6 (0.40) | ABHD6ESR1ESR2NOTUMNPC1 | |
| SCHEMBL29405503 | 0.80 | ESR2 (0.55) | ABHD6ESR2MAPT | |
| SCHEMBL19642882 | 0.80 | ESR2 (0.55) | ABHD6ESR2MAPT | |
| SCHEMBL30597676 | 0.79 | ABHD6 (0.36) | ABHD6ESR1ESR2NOTUMNPC1 | |
| SCHEMBL22981183 | 0.79 | KCNJ1 (0.37) | ABHD6ESR1ESR2NOTUMNPC1 | |
| SCHEMBL25409148 | 0.79 | TMEM97 (0.53) | MEN1MAPTKMT2A | |
| SCHEMBL31107122 | 0.79 | TMEM97 (0.53) | MEN1MAPTKMT2A | |
| SCHEMBL1550147 | 0.78 | ABHD6 (0.60) | ABHD6AKR1C3NOTUMNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | Sumitomo Pharma Co., Ltd. (JP) | 2022-09-06 | — | — | US | disclosed |
| EP-4010333-A1 | PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021028645-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028649-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| EP-3560494-A1 | DRUG TARGETING CANCER STEM CELL | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | ABHD6 4362/4885AKR1C3 513/4885ESR1 1678/4885 |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | SALL4, NR4A2, NES | ABHD6 4260/4885AKR1C3 605/4885ESR1 752/4885 |
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | NR5A1, NR3C1, NR3C2 | ABHD6 2590/4885AKR1C3 223/4885ESR1 892/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | ABHD6 4362/4885AKR1C3 513/4885ESR1 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.